Pharmafile - Research and Development News
New positive data for Janssen's esketamine depression treatment, MSD buys Peloton Therapeutics for $2.1 billion, and Gilead CEO grilled on why its...
New findings from researchers at King’s College London could lead to improved vaccinations against sexually transmitted infections (STIs).
Array Biopharma's Braftovi triple therapy meets both endpoints in advanced colorectal cancer subtype
Array Biopharma has revealed new data on its combination of Braftovi, Mektovi, and Erbitux, showing that it met both of its primary endpoints in the...
California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million).
Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in the...
MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion.
Children wait six and half years longer than adults to access new cancer drugs, according to a study from Dana-Farber/Boston Children's Cancer and...
New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the FDA in the US in...
Researchers at Imperial College London (ICL) and Johannes Gutenberg University Mainz have shown that xenon prevents early death and long-term...
MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase 3 study evaluating its...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
